A Bayesian perspective on Biogen's aducanumab trial-Reference-Cited by-同舟云学术

A Bayesian perspective on Biogen's aducanumab trial

Published:2022-03-02 Issue:11 Volume:18 Page:2341-2351
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Temp Anna G. M.¹²^ORCID,Ly Alexander³⁴,van Doorn Johnny³,Wagenmakers Eric‐Jan³,Tang Yi⁵,Lutz Michael W.⁶,Teipel Stefan¹⁷

Affiliation:

1. German Center for Neurodegenerative Diseases (DZNE) Rostock Germany

2. Translational Neurodegeneration Section “Albrecht Kossel,” Department of Neurology University of Rostock Rostock Germany

3. Department of Psychological Methods University of Amsterdam Amsterdam the Netherlands

4. Machine Learning Group Centrum Wiskunde & Informatica Amsterdam the Netherlands

5. Department of Neurology Xuanwu Hospital National Center for Neurological Disorders Capital Medical University Beijing China

6. Department of Neurology Duke University School of Medicine Durham North Carolina USA

7. Department of Psychosomatic Medicine and Psychotherapy University Medicine Rostock Rostock Germany

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12615

Reference41 articles.

1. Bayesian inference for psychology. Part I: Theoretical advantages and practical ramifications

2. The fallacy of placing confidence in confidence intervals

3. Redefine statistical significance

4. A Dirty Dozen: Twelve P-Value Misconceptions

5. Three common misuses ofPvalues

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of transcranial direct current stimulation on cognition in MCI with Alzheimer's disease risk factors using Bayesian analysis;Scientific Reports;2024-08-13

2. MRI-informed machine learning-driven brain age models for classifying mild cognitive impairment converters;Journal of Central Nervous System Disease;2024-07-21

3. Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review;Alzheimer's Research & Therapy;2024-04-27

4. Bayesian meta‐analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high‐dose gantenerumab in prodromal and mild Alzheimer's disease;Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-01

5. Minimally Invasive Surgery With Thrombolysis for Intracerebral Hemorrhage Evacuation;Neurology;2023-10-17